curcumin and Hyperpigmentation

The main aim of the present study was to develop curcumin (CUR) loaded permeation enhancer-lipid vesicles for the treatment of hyperpigmentation. Hyperpigmentation is an acquired skin disorder characterized by uneven skin coloration, mainly in the regions of the facial skin, affecting millions of people worldwide. It often occurs in visible areas, hence causing significant negative psychological and social impacts. In the present study, curcumin-loaded permeation enhancer nanovesicles (PE-NVs) were developed by modified ethanol injection method and dimethyl sulfoxide was added as a penetration enhancer. PE-NVs were subjected to various physicochemical characterizations and drug permeation studies across the skin. The PE-NVs were tested for their efficacy in a sunlight-induced hyperpigmented rabbit skin model. Topical application of PE-NVs reduced symptoms of hyperpigmentation as compared with CUR methanolic solution because of higher accumulation because of better permeation into skin layers. Histopathological studies also confirmed the effectiveness of PE-NVs, since they reduced hyperpigmentation-induced lesions. Results confirmed that PE-NVs is a potential drug delivery system for topical administration drugs to treat skin-associated inflammatory disorders.

Topics: Animals; Curcumin; Hyperpigmentation; Liposomes; Rabbits; Skin; Skin Absorption

Hyperpigmentation is a dermatological condition characterized by the overaccumulation and/or oversecretion of melanin pigment. The efficacy of curcumin as an anti-melanogenic therapeutic has been recognized, but the poor stability and solubility that have limited its use have inspired the synthesis of novel curcumin analogs. We have previously reported on comparisons of the anti-melanogenic activity of four novel chemically modified curcumin (CMC) analogs, CMC2.14, CMC2.5, CMC2.23 and CMC2.24, with that of parent curcumin (PC), using a B16F10 mouse melanoma cell model, and we have investigated mechanisms of inhibition. In the current study, we have extended our findings using normal human melanocytes from a darkly pigmented donor (HEMn-DP) and we have begun to study aspects of melanosome export to human keratinocytes. Our results showed that all the CMCs downregulated the protein levels of melanogenic paracrine mediators, endothelin-1 (ET-1) and adrenomedullin (ADM) in HaCaT cells and suppressed the phagocytosis of FluoSphere beads that are considered to be melanosome mimics. All the three CMCs were similarly potent (except CMC2.14, which was highly cytotoxic) in inhibiting melanin production; furthermore, they suppressed dendricity in HEMn-DP cells. CMC2.24 and CMC2.23 robustly suppressed cellular tyrosinase activity but did not alter tyrosinase protein levels, while CMC2.5 did not suppress tyrosinase activity but significantly downregulated tyrosinase protein levels, indicative of a distinctive mode of action for the two structurally related CMCs. Moreover, HEMn-DP cells treated with CMC2.24 or CMC2.23 partially recovered their suppressed tyrosinase activity after cessation of the treatment. All the three CMCs were nontoxic to human dermal fibroblasts while PC was highly cytotoxic. Our results provide a proof-of-principle for the novel use of the CMCs for skin depigmentation, since at low concentrations, ranging from 5 to 25 µM, the CMCs (CMC2.24, CMC2.23 and CMC2.5) were more potent anti-melanogenic agents than PC and tetrahydrocurcumin (THC), both of which were ineffective at melanogenesis at similar doses, as tested in HEMn-DP cells (with PC being highly toxic in dermal fibroblasts and keratinocytes). Further studies to evaluate the efficacy of CMCs in human skin tissue and in vivo studies are warranted.

Topics: Adrenomedullin; Animals; Curcumin; Endothelin-1; Humans; Hyperpigmentation; Keratinocytes; Melanins; Melanocytes; Melanoma, Experimental; Melanosomes; Mice; Phagocytosis; Skin

Irritant contact dermatitis (ICD) and hyperpigmentation are the problems associated with skin. Topical curcumin (CUR) although effective in hyperpigmentation and ICD, is a challenging molecule due to low-solubility. Encapsulation of CUR into solid lipid nanoparticles (SLNs) makes it amenable to topical dosing as their small size promotes its penetration into the skin. CUR-SLNs were prepared using Precirol ATO5 and Tween-80 by probe ultrasonication method. Further, CUR-SLNs were incorporated into Carbopol gel and investigated for ex-vivo skin permeation, skin deposition and skin irritation studies. The potential of CUR-SLN gel was checked against hyperpigmentation through the inhibition of tyrosinase enzyme. It was further evaluated for possible effects on ICD using BALB/c mice. The optimized CUR-SLN showed the particle size of 51 nm and 93% EE. Ex vivo permeation of CUR-SLN gel exhibited controlled drug release up to 24 h, similarly in vitro drug deposition studies showed potential for skin targeting. In vitro tyrosinase inhibition assay indicates that the formulated gel has potential in skin depigmentation. The gel also confirmed proficient suppression of ear swelling and reduction in skin water content in the BALB/c mouse. Thus, the CUR-SLN gel would be a safe and effective alternative to conventional vehicles for treatment of ICD and pigmentation.

Topics: Administration, Topical; Animals; Curcumin; Dermatitis, Contact; Diffusion; Drug Carriers; Gels; Hyperpigmentation; Irritants; Lipids; Mice; Monophenol Monooxygenase; Nanoparticles; Skin; Solubility

This study investigated the anti-melanogenic effect of aromatic (ar)-turmerone on alpha-melanocyte stimulating hormone (α-MSH) and 3-isobuty-1-methxlzanthine (IBMX)-induced tyrosinase (Tyr), tyrosinase-related protein 1 (TRP-1), and tyrosinase-related protein 2 (TRP-2) expression in B16F10 melanoma cells. We demonstrated that ar-turmerone inhibits α-MSH and IBMX-induced melanin synthesis and tyrosinase activity. Data also showed that ar-turmerone inhibits the expression of tyrosinase, TRP-1, and TRP-2 in α-MSH- and IBMX-stimulated B16F10 cells. In addition, ar-turmerone exhibits stronger anti-melanogenic effects than curcumin. Furthermore, ar-turmerone strongly inhibited α-MSH- and IBMX-induced microphthalmia-associated transcription factor by suppressing the activity of cyclic adenosine monophosphate (cAMP)-responsive element binding protein in α-MSH-stimulated B16F10 cells. Our data revealed that ar-turmerone is a novel, effective, anti-melanogenic agent that functions by downregulating tyrosinase, Trp-1, and Trp-2 gene expression. Therefore, ar-turmerone may be a useful therapeutic agent for treating hyperpigmentation disorders, such as freckles and melasma, and as a beneficial additive in whitening cosmetics.

Topics: 1-Methyl-3-isobutylxanthine; alpha-MSH; Animals; Cosmetics; Curcuma; Curcumin; Cyclic AMP; Enzyme Activation; Gene Expression Regulation; Hydrocarbons, Aromatic; Hyperpigmentation; Interferon Type I; Intramolecular Oxidoreductases; Melanins; Melanoma, Experimental; Mice; Microphthalmia-Associated Transcription Factor; Monophenol Monooxygenase; Pregnancy Proteins